Two of Bambusa’s bispecific antibody candidates for immunological and inflammatory disorders are set to enter the clinic in ...

Innovative Bispecific Antibody Therapies in Cancer Treatment Emerge as Patent Filings SurgeDublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody & Cancer Patent Landscape Analysis" report ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

In autoimmune diseases such as inflammatory bowel disease (IBD), the function of regulatory CD8 T cells (CD8 Treg) is compromised, in part due to the expression of inhibitory KIR receptors ...

The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

Akeso Inc. has received IND approval by China’s National Medical Products Administration (NMPA) for AK-139, an IL-4Rα/ST2 ...

A review of recent trends and remaining challenges in bispecific antibody (bsAb) production has been published.

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...

Bispecific antibody drug conjugates (ADCs) represent an innovative advancement in cancer therapy, combining the dual-targeting capability of bispecific antibodies with the potent cytotoxic effects of ...